Financial Assistance
Newsletter Sign-up
Need Appointment
Contact Us
About Us

Rush University
For Physicians
For Rush Employees
For Students
Bill Payment Center
Rotate

Mark H. Pollack, MD

Mark H. Pollack, MD
Appointment Request

Or call
(888) 352-RUSH for help arranging an appointment.
Specialty:
  • Psychiatry
Board Certification:
  • Psychiatry
Faculty Rank: Professor
Medical or Graduate Education: New Jersey Medical School
Residency: Massachusetts General Hospital - Psychiatry
Fellowship: Massachusetts General Hospital - Psychiatry
Clinical Expertise:
  • Addiction
  • Anxiety
  • Bipolar disorder
  • Depression
  • Mood disorders
  • Obsessive-compulsive disorder (OCD)
  • Panic disorder
  • Phobias
  • Post-traumatic stress disorder (PTSD)
  • Psychopharmacology integrated with medical management
  • Traumatic stress
Research Interests:
  • Acute and long-term course and treatment of anxiety and traumatic stress disorders
  • Development of novel therapuetics for mood and anxiety disorders
  • Combined cognitive-behavioral and pharmacotherapy for anxiety disorders
  • Treatment refractory mood and anxiety disorders
  • Pathophysiology and treatment of substance abuse
Languages Spoken:
  • English
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. De novo fear conditioning across diagnostic groups in the affective disorders: evidence for learning impairments.
    Otto MW, Moshier SJ, Kinner DG, Simon NM, Pollack MH, Orr SP
    Behav Ther
    2014 Sep
    45(5):619-29.
  2. Influence of RGS2 on sertraline treatment for social anxiety disorder.
    Stein MB, Keshaviah A, Haddad SA, Van Ameringen M, Simon NM, Pollack MH, Smoller JW
    Neuropsychopharmacology
    2014 May
    39(6):1340-6.
  3. Response to silberman.
    Pollack MH, Stein M, Simon N, Van Ameringen M
    Am J Psychiatry
    2014 Jul 1
    171(7):795-6.
  4. The Human Ortholog of Acid-Sensing Ion Channel Gene ASIC1a Is Associated with Panic Disorder and Amygdala Structure and Function.
    Smoller JW, Gallagher PJ, Duncan LE, McGrath LM, Haddad SA, Holmes AJ, Wolf AB, Hilker S, Block SR, Weill S, Young S, Choi EY, Rosenbaum JF, Biederman J, Faraone SV, Roffman JL, Manfro GG, Blaya C, Hirshfeld-Becker DR, Stein MB, Van Ameringen M, Tolin DF, Otto MW, Pollack MH, Simon NM, Buckner RL, Ongür D, Cohen BM
    Biol. Psychiatry
    2014 Jan 18
  5. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder.
    Pollack MH, Van Ameringen M, Simon NM, Worthington JW, Hoge EA, Keshaviah A, Stein MB
    Am J Psychiatry
    2014 Jan 1
    171(1):44-53.
  6. Two weeks of pretreatment with escitalopram facilitates extinction learning in healthy individuals.
    Bui E, Orr SP, Jacoby RJ, Keshaviah A, Leblanc NJ, Milad MR, Pollack MH, Simon NM
    Hum Psychopharmacol
    2013 Sep
    28(5):447-56.
  7. d-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions.
    Smits JA, Rosenfield D, Otto MW, Marques L, Davis ML, Meuret AE, Simon NM, Pollack MH, Hofmann SG
    J Psychiatr Res
    2013 Oct
    47(10):1455-61.
  8. Voxel-based morphometric gray matter correlates of posttraumatic stress disorder.
    Weber M, Killgore WD, Rosso IM, Britton JC, Schwab ZJ, Weiner MR, Simon NM, Pollack MH, Rauch SL
    J Anxiety Disord
    2013 May
    27(4):413-9.
  9. Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity.
    Hoge EA, Bui E, Marques L, Metcalf CA, Morris LK, Robinaugh DJ, Worthington JJ, Pollack MH, Simon NM.
    J Clin Psychiatry. 2013
    2013 Mar 13. [Epub ahead of print]
  10. CORTICO-LIMBIC RESPONSES TO MASKED AFFECTIVE FACES ACROSS PTSD, PANIC DISORDER, AND SPECIFIC PHOBIA.
    Killgore WD, Britton JC, Schwab ZJ, Price LM, Weiner MR, Gold AL, Rosso IM, Simon NM, Pollack MH, Rauch SL
    Depress Anxiety
    2013 Jul 16
  11. D-Cycloserine Enhancement of Fear Extinction is Specific to Successful Exposure Sessions: Evidence from the Treatment of Height Phobia.
    Smits JA, Rosenfield D, Otto MW, Powers MB, Hofmann SG, Telch MJ, Pollack MH, Tart CD.
    Biol Psychiatry. 2013
    2013 Jan 16. doi:pii: S0006-3223(12)01094-3. 10.1016/j.biopsych.2012.12.009. [Epub ahead of print]
  12. Predictors of dropout from psychosocial treatment in opioid-dependent outpatients.
    McHugh RK, Murray HW, Hearon BA, Pratt EM, Pollack MH, Safren SA, Otto MW.
    Am J Addict. 2013
    2013 Jan
    22(1):18-22. doi: 10.1111/j.1521-0391.2013.00317.x.
  13. Augmentation of exposure therapy with post-session administration of d-cycloserine.
    Tart CD, Handelsman PR, Deboer LB, Rosenfield D, Pollack MH, Hofmann SG, Powers MB, Otto MW, Smits JA.
    J Psychiatr Res. 2013
    2013 Feb
    47(2):168-74. doi: 10.1016/j.jpsychires.2012.09.024. Epub 2012 Oct 23.
  14. Development of a Brief Version of the Social Phobia Inventory Using Item Response Theory: The Mini-SPIN-R.
    Aderka IM, Pollack MH, Simon NM, Smits JA, Van Ameringen M, Stein MB, Hofmann SG
    Behav Ther
    2013 Dec
    44(4):651-661.
  15. Smiles may go unseen in generalized social anxiety disorder: Evidence from binocular rivalry for reduced visual consciousness of positive facial expressions.
    Anderson EC, Dryman MT, Worthington J, Hoge EA, Fischer LE, Pollack MH, Barrett LF, Simon NM
    J Anxiety Disord
    2013 Aug 6
    27(7):619-626.
  16. SLEEP QUALITY PREDICTS TREATMENT OUTCOME IN CBT FOR SOCIAL ANXIETY DISORDER.
    Zalta AK, Dowd S, Rosenfield D, Smits JA, Otto MW, Simon NM, Meuret AE, Marques L, Hofmann SG, Pollack MH
    Depress Anxiety
    2013 Aug 26
  17. D-Cycloserine Augmentation of Cognitive Behavioral Group Therapy of Social Anxiety Disorder: Prognostic and Prescriptive Variables.
    Smits JA, Hofmann SG, Rosenfield D, Deboer LB, Costa PT, Simon NM, O'Cleirigh C, Meuret AE, Marques L, Otto MW, Pollack MH
    J Consult Clin Psychol
    2013 Aug 12
  18. Loving-Kindness Meditation practice associated with longer telomeres in women.
    Hoge EA, Chen MM, Orr E, Metcalf CA, Fischer LE, Pollack MH, Devivo I, Simon NM.
    Brain Behav Immun. 2013
    2013 Apr 19. doi:pii: S0889-1591(13)00173-6. 10.1016/j.bbi.2013.04.005. [Epub ahead of print]
  19. d-Cycloserine as an Augmentation Strategy With Cognitive-Behavioral Therapy for Social Anxiety Disorder.
    Hofmann SG, Smits JA, Rosenfield D, Simon N, Otto MW, Meuret AE, Marques L, Fang A, Tart C, Pollack MH.
    Am J Psychiatry. 2013
    2013 Apr 19. doi: 10.1176/appi.ajp.2013.12070974. [Epub ahead of print]
  20. Predicting Treatment Response in Social Anxiety Disorder From Functional Magnetic Resonance Imaging.
    Doehrmann O, Ghosh SS, Polli FE, Reynolds GO, Horn F, Keshavan A, Triantafyllou C, Saygin ZM, Whitfield-Gabrieli S, Hofmann SG, Pollack M, Gabrieli JD.
    Arch Gen Psychiatry. 2012
    2012 Sep 3:1-11. doi: 10.1001/2013.jamapsychiatry.5. [Epub ahead of print]
  21. Plasma oxytocin immunoreactive products and response to trust in patients with social anxiety disorder.
    Hoge EA, Lawson EA, Metcalf CA, Keshaviah A, Zak PJ, Pollack MH, Simon NM.
    Depress Anxiety. 2012
    2012 Nov
    29(11):924-30. doi: 10.1002/da.21973. Epub 2012 Jul 17.
  22. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M.
    J Clin Psychiatry. 2012
    2012 Mar
    73(3):353-7. doi: 10.4088/JCP.10m06541. Epub 2011 Sep 20.
  23. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial.
    Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH.
    J Consult Clin Psychol. 2012
    2012 Jun
    80(3):404-15. doi: 10.1037/a0028208. Epub 2012 Apr 30.
  24. Anchoring the Panic Disorder Severity Scale.
    Keough ME, Porter E, Kredlow MA, Worthington JJ, Hoge EA, Pollack MH, Shear MK, Simon NM.
    Assessment. 2012
    2012 Jun
    19(2):257-9. doi: 10.1177/1073191112436668. Epub 2012 Feb 11.
  25. Sexual HIV risk behaviors in a treatment-refractory opioid-dependent sample.
    McHugh RK, Weitzman M, Safren SA, Murray HW, Pollack MH, Otto MW.
    J Psychoactive Drugs. 2012
    2012 Jul-Aug
    44(3):237-42.
  26. Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery.
    Hoge EA, Worthington JJ, Nagurney JT, Chang Y, Kay EB, Feterowski CM, Katzman AR, Goetz JM, Rosasco ML, Lasko NB, Zusman RM, Pollack MH, Orr SP, Pitman RK.
    CNS Neurosci Ther. 2012
    2012 Jan
    18(1):21-7. doi: 10.1111/j.1755-5949.2010.00227.x. Epub 2011 Jan 10.
  27. Treatment change of somatic symptoms and cultural syndromes among Cambodian refugees with PTSD.
    Hinton DE, Kredlow MA, Bui E, Pollack MH, Hofmann SG.
    Depress Anxiety. 2012
    2012 Feb
    29(2):147-54. doi: 10.1002/da.20905. Epub 2011 Nov 7.
  28. Avoidant personality disorder in individuals with generalized social anxiety disorder: what does it add?
    Marques L, Porter E, Keshaviah A, Pollack MH, Van Ameringen M, Stein MB, Simon NM.
    J Anxiety Disord. 2012
    2012 Aug
    26(6):665-72. doi: 10.1016/j.janxdis.2012.05.004. Epub 2012 May 27.
  29. Mood regulation and quality of life in social anxiety disorder: an examination of generalized expectancies for negative mood regulation.
    Sung SC, Porter E, Robinaugh DJ, Marks EH, Marques LM, Otto MW, Pollack MH, Simon NM.
    J Anxiety Disord. 2012
    2012 Apr
    26(3):435-41. doi: 10.1016/j.janxdis.2012.01.004. Epub 2012 Jan 16.
  30. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
    Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M.
    Psychother Psychosom. 2012
    2012
    81(2):87-97. doi: 10.1159/000332050. Epub 2012 Jan 25. Erratum in: Psychother Psychosom. 2012;81(4):261.
  31. The role of anxiety sensitivity in sleep disturbance in panic disorder.
    Hoge EA, Marques L, Wechsler RS, Lasky AK, Delong HR, Jacoby RJ, Worthington JJ, Pollack MH, Simon NM.
    J Anxiety Disord.
    2011 May
    25(4):536-8
  32. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial.
    Pollack MH, Hoge EA, Worthington JJ, Moshier SJ, Wechsler RS, Brandes M, Simon NM.
    J Clin Psychiatry. 2011
    2011 Jul
    72(7):892-7. doi: 10.4088/JCP.09m05607gry. Epub 2011 Feb 22.
  33. Understanding the relationship of perceived social support to post-trauma cognitions and posttraumatic stress disorder.
    Robinaugh DJ, Marques L, Traeger LN, Marks EH, Sung SC, Gayle Beck J, Pollack MH, Simon NM.
    J Anxiety Disord. 2011
    2011 Dec
    25(8):1072-8. doi: 10.1016/j.janxdis.2011.07.004. Epub 2011 Jul 19.
  34. Culturally adapted CBT (CA-CBT) for Latino women with treatment-resistant PTSD: a pilot study comparing CA-CBT to applied muscle relaxation.
    Hinton DE, Hofmann SG, Rivera E, Otto MW, Pollack MH.
    Behav Res Ther. 2011
    2011 Apr
    49(4):275-80. doi: 10.1016/j.brat.2011.01.005. Epub 2011 Jan 27.
  35. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ).
    Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M.
    CNS Neurosci Ther. 2010
    2010 Oct
    16(5):322-5. doi: 10.1111/j.1755-5949.2009.00102.x.
  36. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial.
    Stein MB, Ravindran LN, Simon NM, Liebowitz MR, Khan A, Brawman-Mintzer O, Lydiard RB, Pollack MH.
    J Clin Psychiatry. 2010
    2010 May
    71(5):627-31. doi: 10.4088/JCP.08m04949gre. Epub 2009 Dec 15.
  37. Khyâl attacks: a key idiom of distress among traumatized cambodia refugees.
    Hinton DE, Pich V, Marques L, Nickerson A, Pollack MH.
    Cult Med Psychiatry. 2010
    2010 Jun
    34(2):244-78. doi: 10.1007/s11013-010-9174-y.
  38. Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response.
    Simon NM, Worthington JJ, Moshier SJ, Marks EH, Hoge EA, Brandes M, Delong H, Pollack MH.
    CNS Spectr. 2010
    2010 Jul
    15(7):367-73.
  39. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder.
    Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH.
    Biol Psychiatry. 2010
    2010 Feb 15
    67(4):365-70. doi: 10.1016/j.biopsych.2009.07.036. Epub 2009 Oct 6.
  40. Rates of mood and anxiety disorders and contributors to continued heroin use in methadone maintenance patients: A comparison by HIV status.
    Applebaum AJ, Bullis JR, Traeger LN, O'cleirigh C, Otto MW, Pollack MH, Safren SA
    Neurobehav HIV Med
    2010 Aug 10
    2010(2):49-57.
  41. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation.
    Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH.
    Behav Res Ther. 2010
    2010 Aug
    48(8):720-7. doi: 10.1016/j.brat.2010.04.002. Epub 2010 Apr 28.
  42. Open-label support for duloxetine for the treatment of panic disorder.
    Simon NM, Kaufman RE, Hoge EA, Worthington JJ, Herlands NN, Owens ME, Pollack MH.
    CNS Neurosci Ther. 2009
    2009 Winter
    15(1):19-23. doi: 10.1111/j.1755-5949.2008.00076.x.
  43. A comparison of emotional approach coping (EAC) between individuals with anxiety disorders and nonanxious controls.
    Marques L, Kaufman RE, LeBeau RT, Moshier SJ, Otto MW, Pollack MH, Simon NM.
    CNS Neurosci Ther. 2009
    2009 Summer
    15(2):100-6. doi: 10.1111/j.1755-5949.2009.00080.x.
  44. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.
    Simon NM, Otto MW, Worthington JJ, Hoge EA, Thompson EH, Lebeau RT, Moshier SJ, Zalta AK, Pollack MH.
    J Clin Psychiatry. 2009
    2009 Nov
    70(11):1563-70. doi: 10.4088/JCP.08m04485blu. Epub 2009 Oct 6.
  45. Anger, PTSD, and the nuclear family: a study of Cambodian refugees.
    Hinton DE, Rasmussen A, Nou L, Pollack MH, Good MJ.
    Soc Sci Med. 2009
    2009 Nov
    69(9):1387-94. doi: 10.1016/j.socscimed.2009.08.018. Epub 2009 Sep 10.
  46. Nightmares among Cambodian refugees: the breaching of concentric ontological security.
    Hinton DE, Hinton AL, Pich V, Loeum JR, Pollack MH.
    Cult Med Psychiatry.
    2009 Jun
    33(2):219-65.
  47. A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder.
    Evans KC, Simon NM, Dougherty DD, Hoge EA, Worthington JJ, Chow C, Kaufman RE, Gold AL, Fischman AJ, Pollack MH, Rauch SL.
    Neuropsychopharmacology. 2009
    2009 Jan
    34(2):390-8. doi: 10.1038/npp.2008.69. Epub 2008 Jun 4.
  48. Anxiety disorder presentations in Asian populations: a review.
    Hinton DE, Park L, Hsia C, Hofmann S, Pollack MH.
    CNS Neurosci Ther. 2009
    2009 Fall
    15(3):295-303. doi: 10.1111/j.1755-5949.2009.00095.x. Review.
  49. Introduction to the special issue: anxiety disorders in cross-cultural perspective.
    Hinton DE, Pollack MH.
    CNS Neurosci Ther. 2009
    2009 Fall
    15(3):207-9. doi: 10.1111/j.1755-5949.2009.00097.x.
  50. A model of the generation of ataque de nervios: the role of fear of negative affect and fear of arousal symptoms.
    Hinton DE, Lewis-Fernández R, Pollack MH.
    CNS Neurosci Ther. 2009
    2009 Fall
    15(3):264-75. doi: 10.1111/j.1755-5949.2009.00101.x.
  51. Mechanisms of efficacy of CBT for Cambodian refugees with PTSD: improvement in emotion regulation and orthostatic blood pressure response.
    Hinton DE, Hofmann SG, Pollack MH, Otto MW.
    CNS Neurosci Ther. 2009
    2009 Fall
    15(3):255-63. doi: 10.1111/j.1755-5949.2009.00100.x.
  52. Brain GABA levels in patients with bipolar disorder.
    Kaufman RE, Ostacher MJ, Marks EH, Simon NM, Sachs GS, Jensen JE, Renshaw PF, Pollack MH.
    Prog Neuropsychopharmacol Biol Psychiatry. 2009
    2009 Apr 30
    33(3):427-34. doi: 10.1016/j.pnpbp.2008.12.025. Epub 2009 Jan 10.
  53. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder.
    Hoge EA, Brandstetter K, Moshier S, Pollack MH, Wong KK, Simon NM.
    Depress Anxiety.
    2009
    26(5):447-55.
  54. Childhood maltreatment linked to greater symptom severity and poorer quality of life and function in social anxiety disorder.
    Simon NM, Herlands NN, Marks EH, Mancini C, Letamendi A, Li Z, Pollack MH, Van Ameringen M, Stein MB.
    Depress Anxiety. 2009
    2009
    26(11):1027-32. doi: 10.1002/da.20604.
  55. Refractory generalized anxiety disorder.
    Pollack MH.
    J Clin Psychiatry. 2009
    2009
    70 Suppl 2:32-8. Review.
  56. Redefining affective disorders: relevance for drug development.
    Targum SD, Pollack MH, Fava M.
    CNS Neurosci Ther. 2008
    2008 Spring
    14(1):2-9. doi: 10.1111/j.1527-3458.2008.00038.x. Review.
  57. Changing times at CNS Neuroscience & Therapeutics.
    Pollack MH.
    CNS Neurosci Ther. 2008
    2008 Spring
    14(1):1. doi: 10.1111/j.1527-3458.2008.00039.x. No abstract available.
  58. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment.
    Pollack MH, Endicott J, Liebowitz M, Russell J, Detke M, Spann M, Ball S, Swindle R.
    J Psychiatr Res. 2008
    2008 Oct
    42(12):1042-9. doi: 10.1016/j.jpsychires.2007.11.006. Epub 2008 Jan 24.
  59. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint.
    Pollack MH, Kornstein SG, Spann ME, Crits-Christoph P, Raskin J, Russell JM.
    J Psychiatr Res. 2008
    2008 Oct
    42(14):1176-84. doi: 10.1016/j.jpsychires.2008.02.002. Epub 2008 Mar 17.
  60. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings.
    Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ 3rd, Zhang W, Davidson JR, Pollack MH.
    Psychopharmacology (Berl). 2008
    2008 May
    197(4):675-81. doi: 10.1007/s00213-008-1087-x. Epub 2008 Feb 2.
  61. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.
    Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R.
    Arch Gen Psychiatry. 2008
    2008 May
    65(5):551-62. doi: 10.1001/archpsyc.65.5.551.
  62. A detailed examination of cytokine abnormalities in Major Depressive Disorder.
    Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK.
    Eur Neuropsychopharmacol.
    2008 Mar
    18(3):230-3
  63. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy.
    Simon NM, Connor KM, Lang AJ, Rauch S, Krulewicz S, LeBeau RT, Davidson JR, Stein MB, Otto MW, Foa EB, Pollack MH.
    J Clin Psychiatry. 2008
    2008 Mar
    69(3):400-5.
  64. Anxiety is associated with impulsivity in bipolar disorder.
    Taylor CT, Hirshfeld-Becker DR, Ostacher MJ, Chow CW, LeBeau RT, Pollack MH, Nierenberg AA, Simon NM.
    J Anxiety Disord. 2008
    2008 Jun
    22(5):868-76. Epub 2007 Sep 11.
  65. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder.
    Hoge EA, Worthington JJ 3rd, Kaufman RE, Delong HR, Pollack MH, Simon NM.
    CNS Spectr. 2008
    2008 Jun
    13(6):522-7.
  66. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
    Pollack MH, Tiller J, Xie F, Trivedi MH.
    J Clin Psychopharmacol. 2008
    2008 Jun
    28(3):308-16. doi: 10.1097/JCP.0b013e318172b45f.
  67. The 'multiplex model' of somatic symptoms: application to tinnitus among traumatized Cambodian refugees.
    Hinton DE, Hinton SD, Loeum RJ, Pich V, Pollack MH.
    Transcult Psychiatry. 2008
    2008 Jun
    45(2):287-317. doi: 10.1177/1363461508089768.
  68. Oxytocin levels in social anxiety disorder.
    Hoge EA, Pollack MH, Kaufman RE, Zak PJ, Simon NM.
    CNS Neurosci Ther. 2008
    2008 Fall
    14(3):165-70. doi: 10.1111/j.1755-5949.2008.00051.x.
  69. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies.
    Davidson J, Allgulander C, Pollack MH, Hartford J, Erickson JS, Russell JM, Perahia D, Wohlreich MM, Carlson J, Raskin J.
    Hum Psychopharmacol. 2008
    2008 Aug
    23(6):519-26. doi: 10.1002/hup.949.
  70. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam.
    Pollack MH, Jensen JE, Simon NM, Kaufman RE, Renshaw PF.
    Prog Neuropsychopharmacol Biol Psychiatry. 2008
    2008 Apr 1
    32(3):739-43. doi: 10.1016/j.pnpbp.2007.11.023. Epub 2007 Nov 28.
  71. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders.
    George MS, Ward HE Jr, Ninan PT, Pollack M, Nahas Z, Anderson B, Kose S, Howland RH, Goodman WK, Ballenger JC.
    Brain Stimul. 2008
    2008 Apr
    1(2):112-21. doi: 10.1016/j.brs.2008.02.001. Epub 2008 Mar 28.
  72. Novel treatment approaches for refractory anxiety disorders.
    Pollack MH, Otto MW, Roy-Byrne PP, Coplan JD, Rothbaum BO, Simon NM, Gorman JM.
    Depress Anxiety.
    2008
    25(6):467-76.
  73. Ataque de nervios: relationship to anxiety sensitivity and dissociation predisposition.
    Hinton DE, Chong R, Pollack MH, Barlow DH, McNally RJ.
    Depress Anxiety.
    2008
    25(6):489-95.
  74. Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy.
    Olatunji BO, Feldman G, Smits JA, Christian KM, Zalta AK, Pollack MH, Simon NM.
    Depress Anxiety.
    2008
    25(2):167-71.
  75. The panic attack-posttraumatic stress disorder model: applicability to orthostatic panic among Cambodian refugees.
    Hinton DE, Hofmann SG, Pitman RK, Pollack MH, Barlow DH.
    Cogn Behav Ther.
    2008
    37(2):101-16.
  76. A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder.
    Evans KC, Wright CI, Wedig MM, Gold AL, Pollack MH, Rauch SL.
    Depress Anxiety.
    2008
    25(6):496-505.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript

Find a Doctor | Patient & Visitor Services | Health Information | Clinical Services | Events & Classes | News Room | Clinical Trials | Research at Rush
Nursing at Rush | Work at Rush | Giving to Rush | Directions to Rush | Disclaimer | Privacy Statement
For Physicians | For Rush Employees | For Students | Bill Payment Center | Site Map
© Rush University Medical Center
1653 W. Congress Parkway, Chicago, Illinois 60612